We recently compiled a list of the Jim Cramer Recently Discussed These 7 Stocks. In this article, we are going to take a look at where TransMedics Group, Inc. (NASDAQ:TMDX) stands against the other stocks Jim Cramer recently discussed.
Jim Cramer, host of Mad Money, recently shared his thoughts on how geopolitical concerns, particularly the recent nuclear threat, can significantly impact investor behavior. He pointed out that when such threats arise, investors typically become more cautious and often seek safer investments, such as U.S. Treasury bonds.
Cramer referred to this phenomenon as a “flight-to-quality,” a pattern that has become particularly noticeable in the context of rising bond yields. He commented:
“We’ve had a bad bond market of late with rates going up and this Russian new concern changed the direction of bonds as these flight-to-quality buyers drove bonds up and interest rates lower.”
Cramer explained that fast traders are well aware of how to react to rising long-term interest rates. Their instinct is to invest in tech stocks, regardless of whether bond rates are actually decreasing. According to Cramer, it’s a predictable move that, when bond prices rise and yields fall, investors inevitably turn to tech stocks.
This holds true even in cases where investors are seeking out treasuries because of a flight to quality or because inflation is easing. He emphasized that, whenever there is a rally in bonds and a dip in bond yields, it’s almost automatic that tech stocks will see increased investment. He added:
“Next time nukes are threatened and you see a flight-to-quality, remember this, the highest quality is the Magnificent Seven.”
READ ALSO Jim Cramer’s Lightning Round: 8 Stocks to Watch and Jim Cramer Is Focused on These 15 Stocks This Week
Cramer also discussed how the market might react to potential trade policy changes, particularly the threat of tariffs under President-elect Donald Trump. He referred to an analysis by Jessica Inskip, the director of investor research at StockBrokers.com, which suggested that the market was largely unaffected by Trump’s pre-election threats of tariffs.
“The charts interpreted by Jessica Inskip suggest that tariffs had little impact on the market until they actually materialized during Trump’s first term, all the saber-rattling beforehand didn’t do much damage. Even when the tariffs actually hit and the market sold off, we eventually erased those losses the moment that the Fed stopped raising interest rates. So until the tariffs actually hit, Inskip says, you can take a page from Taylor Swift and Shake It Off… I think she’s got a real good point.”
Our Methodology
For this article, we compiled a list of 7 stocks that were discussed by Jim Cramer during the recent episodes of Mad Money. We listed the stocks in ascending order of their hedge fund sentiment as of the third quarter, which was taken from Insider Monkey’s database of 900 hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A surgeon in a modern operating theatre performing a transplant surgery with medical technology.
TransMedics Group, Inc. (NASDAQ:TMDX)
Number of Hedge Fund Holders: 32
When Cramer was asked about TransMedics Group, Inc. (NASDAQ:TMDX), he remarked:
“I don’t know how you can really make a lot of money in that business, frankly. I applaud them for doing it, but I just don’t know how you can make the money.”
TransMedics Group (NASDAQ:TMDX) is a medical technology company that transforms organ transplant therapy with its Organ Care System, which preserves and monitors donor organs outside the body while also offering logistics and organ retrieval services. Since its IPO in 2019, the stock is up over 200%. In the third quarter, the company reported a significant 64% increase in revenue year-over-year, which was largely attributed to a rise in the utilization of its Organ Care System.
The company also posted an EPS of $0.12, a reversal from the loss of $0.78 per share reported in the same quarter the previous year. While these results showed strong growth, they did not fully meet market expectations, as analysts had anticipated even greater revenue expansion and a higher EPS.
Despite the shortfall in certain expectations, TransMedics Group (NASDAQ:TMDX) has reaffirmed its full-year revenue guidance, projecting growth of between 76% and 84% compared to 2023. Furthermore, management reiterated its long-term goal to facilitate 10,000 organ transplants annually by 2028, a target that would nearly triple the current number of transplants performed with the assistance of its Organ Care System.
Overall TMDX ranks 6th on our list of the stocks Jim Cramer recently discussed. While we acknowledge the potential of TMDX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than TMDX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
